Abstract
Acute leukemia was the first malignancy to which the principles of adjuvant therapy were applied. In contrast to adjuvant treatment of solid tumors in which surgery and radiation therapy are usually followed by chemotherapy, hematologists used chemotherapy regimens to treat the presenting disease and render the patient free of identifiable tumor (complete remission) then continue to apply post-remission chemotherapy in an adjuvant setting. The response to chemotherapy before surgery and radiation in many solid tumors predicts for duration of survival after radiation and surgery. Likewise, the quality of response to remission induction therapy predicts for duration of complete remission in adult AML.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan EA, and Freireich EJ: Improved prospects for long-term survival in adults with acute myelogenous leukemia. J Am Med Assoc 248:2481–2486, 1982.
Burke PJ: Principles of therapy of malignancy extrapolated from a rat model of leukemia to man. IN: Minimal Residual Disease in Acute Leukemia, Lowenberg B, and Hagenbeek A (eds.). pp. 97–109, 1984.
Keating MJ: Early identification of potentially cured patients with acute myelogenous leukemia: — A recent challenge. IN: Adult Leukemias, vol. 1, Bloomfield CI (ed.). pp. 237–263, 1982.
Freireich EJ, Bodey GP, Harris JE, and Hart JS: Therapy of acute granulocytic leukemia. Cancer Res 27:2573–2577, 1967.
Freireich EJ, Gehan EA, Speer JF, Heilbrun L, Smith TL, Bodey GP, et al.: The usefulness of multiple pretreatment patient characteristics for prediction of response and survival with adult acute leukemia. IN: Advances in the Biosciences: Workshops on Prognostic Factors in Human Acute Leukemia, Fliedner TM and Perry S (eds.). pp. 131–144, 1973.
Gehan EA, Smith TL, Freireich EJ, et al.: Prognostic factors in acute leukemia. Semin Oncol 3:271–282, 1976.
Keating MJ, Smith TL, McCredie KB, et al.: A four-year experience with anthracycline, cytosine arabinoside, vincristine, and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47:2779–2788, 1981.
Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, and Freireich EJ: A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia. Cancer 50:457–465, 1982.
Smith TL, Gehan EA, Keating MJ, and Freireich EJ: Prediction of remission in adult acute leukemia: Development and testing of predictive models. Cancer 50:466–472, 1982.
Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Spitzer G, et al.: Factors related to length of complete remission in adult acute leukemia. Cancer 45:2017–2029, 1980.
Keating MJ: Factors influencing disease free interval after achieving complete remission in acute leukemia. IN: Minimal Residual Disease in Acute Leukemia, Lowenberg B and Hagenbeek A (eds.). pp. 149–164, 1984.
Keating MJ, Cork A, Broach Y, Smith TL, Walters RS, McCredie KB, Trujillo J, and Freireich EJ: Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Research, in press.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishers, Dordrecht
About this chapter
Cite this chapter
Keating, M.J., McCredie, K.B., Freireich, E.J. (1986). Biologic and Treatment Determinants of Curability in Acute Myelogenous Leukemia. In: Hagenbeek, A., Löwenberg, B. (eds) Minimal Residual Disease in Acute Leukemia 1986. Developments in Oncology, vol 45. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-4273-8_14
Download citation
DOI: https://doi.org/10.1007/978-94-009-4273-8_14
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-8398-0
Online ISBN: 978-94-009-4273-8
eBook Packages: Springer Book Archive